Researchers have found genomic, transcriptomic, proteomic, and phenotypic variation in a comparison of HeLa cells across laboratories and over time.
Noninvasive prenatal screening for trisomies and sub-chromosomal alterations uncovered a fragile site expansion and related deletion present in mothers but not fetuses.
Using an integrated omics approach, researchers identified non-muscle invasive bladder cancer subtypes, along with pathways that are frequently altered in the disease.
Expression and copy number profiles from histologically normal duct tissue near tumors suggest a "field of cancerization" may exist in epithelial cells around cancer.
Denmark-based Arcedi would like to commercialize its technology through a major diagnostic company.
A UCLA group and spinout FetoLumina Technologies are working on a clinical assay for noninvasive prenatal diagnostics.
The acquisition allows Sysmex to enter the cytogenetics market and strengthens its technology base in molecular genetics, while expanding its life science business.
In PLOS this week: chromosomal insertion mechanisms, phylogeographic analysis of the Crimean Congo hemorrhagic fever virus, and more.
In PLOS this week: gene expression differences in plants susceptible to or resistant to Plum pox virus, novel human pegivirus, and more.
Microarrays can detect smaller deletions in genes relevant to diseases like acute lymphoblastic leukemia, offering insight into diagnosis, treatment, and prognosis.
Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.
Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.
NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.
In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.